There are 2137 resources available
1145P - Metabolic activity of liver metastases may predict survival in patients with metastatic uveal melanoma
Presenter: Luis del Carpio Huerta
Session: E-Poster Display
Resources:
Abstract
1146P - Rh-endostatin combined with chemotherapy and interferon in the treatment of oral mucosal melanoma without clinical cervical lymph node metastasis: A retrospective study in Chinese population
Presenter: Dongliang Wei
Session: E-Poster Display
Resources:
Abstract
1147P - Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
Presenter: Emilia Cocorocchio
Session: E-Poster Display
Resources:
Abstract
1148P - Multiple primary melanoma incidence trends over five decades, a nationwide population-based study
Presenter: Hildur Helgadottir
Session: E-Poster Display
Resources:
Abstract
1149P - Validation of a model combining clinicopathologic risk factors and a gene expression profile to identify primary melanoma patients who can safely forgo sentinel lymph node biopsy
Presenter: Alexander Meves
Session: E-Poster Display
Resources:
Abstract
1150P - Long-term outcomes of stage IIB-IV melanoma patients: Nationwide data from Norway
Presenter: Anna Winge-Main
Session: E-Poster Display
Resources:
Abstract
1151P - Trends in melanoma mortality in Brazil: A 20-year registry-based study
Presenter: Guilherme Nader Marta
Session: E-Poster Display
Resources:
Abstract
1152P - Influence of dietary and physical exercise habits on the melanoma risk: A case-control study
Presenter: Neus Calbet-llopart
Session: E-Poster Display
Resources:
Abstract
1153TiP - A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study
Presenter: Alexander van Akkooi
Session: E-Poster Display
Resources:
Abstract
1154TiP - A randomized, prospective, multicenter study to assess the impact of early detection of asymptomatic brain metastases (mets) vs standard follow-up on symptomatic brain mets free survival (SBMFS) in pts with previously untreated, unresectable or metastatic melanoma (MM)
Presenter: Eva Munoz Couselo
Session: E-Poster Display
Resources:
Abstract